Loading...

Calithera Biosciences, Inc.

CALA•NASDAQ
Healthcare
Biotechnology
$0.00
$0.00(0.00%)

Calithera Biosciences, Inc. (CALA) Stock Overview

Explore Calithera Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.5/100

Key Financials

Market Cap487
P/E Ratio-0.00
EPS (TTM)$-1.32
ROE0.08%

AI Price Forecasts

1 Week$0.00
1 Month$-0.01
3 Months$0.06
1 Year Target$0.00

CALA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Calithera Biosciences, Inc. (CALA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 487. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for CALAStats details for CALA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CALAAnalyst Recommendations details for CALA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CEO

Stephanie Wong CPA

Employees

8

Headquarters

343 Oyster Point Boulevard, South San Francisco, CA

Founded

2014

Frequently Asked Questions

;